Sanofi
Open
$44.30
Prev. Close
$44.29
High
$44.30
Low
$44.23
Market Snapshot
$111.79B
9.50
$184.86B
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Recently from Cashu
Sanofi Halts Phase 3 MOBILIZE Study, Highlights Challenges in CIDP Therapy Development
Sanofi (Ticker: SNY) announces its decision to discontinue the Phase 3 MOBILIZE study, which evaluated riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not…
Sanofi's Tozorakimab Revolutionizes COPD Treatment with Targeted IL-33 Inhibition
Sanofi's Breakthrough in COPD Treatment: Tozorakimab's Revolutionary Approach Sanofi stands at the forefront of respiratory disease management with its latest innovation, Tozorakimab, a monoclonal ant…
Sanofi Partners with Kali Therapeutics to Advance Immunology Pipeline with KT501 License
Sanofi Expands Immunology Portfolio Through Partnership with Kali Therapeutics Sanofi enhances its foothold in immunology with a licensing agreement for KT501, an innovative tri-specific T-cell engage…
Federal Court Questions U.S. Vaccine Advisory Practices and Public Health Policy Accountability
Federal Court Critiques U.S. Vaccine Advisory Practices: Implications for Public Health Policy In a significant legal development, a federal court raises concerns regarding recent actions by the U.S.…